OphRx

Noninvasive Drug-delivery Technology for Ocular Use

Health Tech & Life Sciences
Active
Seed Tel Aviv-Yafo, Israel Founded 2014
Website ↗ LinkedIn
Last updated 2026-06-18
Total raised
$1.0M
Last: 2014-01
Stage
Seed
Founded
2014
Headcount
6
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

OphRx is developing eye drops based on noninvasive drug delivery that utilize lyotropic liquid crystals as an alternative to current delivery modalities, such as intra-vitreal injections, used to treat diseases at the back of the eye. This platform technology can also be used for front-of-the-eye treatments. OphRx is currently in the preclinical stage of development of two product candidates: OPH-101, an alternative topical treatment to intravitreal injections for wet AMD; and OPH-100, a treatment for DES. OphRx is a XLVision Sciences company, which is fully owned by BioLight Life Sciences Investments.

Funding history · 1 round · $1.0M total

2014-01

Q&A

What is OphRx's primary focus?
OphRx is developing noninvasive drug-delivery technology for ocular use, specifically eye drops that utilize lyotropic liquid crystals as an alternative to current delivery methods for treating eye diseases.
What product candidates is OphRx currently developing?
OphRx is in the preclinical stage of developing two product candidates: OPH-101, a topical treatment for wet AMD, and OPH-100, a treatment for Dry Eye Syndrome (DES).
When was OphRx founded?
OphRx was founded in January 2014.
What is OphRx's current funding stage?
OphRx is currently in the Seed funding stage.
Who are the key investors in OphRx?
In January 2014, OphRx received funding from BIOLIGHT Life Sciences and Kremer & Lieberman groups.
What is the total amount of funding OphRx has raised to date?
OphRx has raised a total of $1,000,000 USD.
Who is the CEO of OphRx?
Sharon Bakalash is the CEO of OphRx.
What is OphRx's relationship with BioLight Life Sciences Investments?
OphRx is a XLVision Sciences company, which is fully owned by BioLight Life Sciences Investments.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
Materials & SubstancesNanomaterials
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Tags

healthcare-providersclinicsdoctorstopical-treatmentnanotechnologypharmaceuticalsophthalmologyeye-diseasesnon-invasivepharma-companiesglaucomamedical-technologiesdrug-delivery
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)